EDGAR·FLOW

Bolt Biotherapeutics, Inc. — Form 8-K

Filed November 12, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 92/100
What the filing says
On October 23, 2026, Bolt completed a stock-for-stock reverse merger with Prana Therapies (paid 430,746 common shares and 16,360.929 Series D preferred shares, convertible to ~16.4M common shares) and a concurrent $120M private placement (13,995.311 Series D preferred shares + warrants). The transaction consolidates PRA-216 (IL-4R/TSLP bispecific in Phase 2 for asthma, COPD, atopic dermatitis) as Bolt's lead program. Post-transaction, Bolt expects ~34.2M common shares outstanding on an as-converted basis. Cash runway extended to 2028. Prana's former CEO joined Bolt's board as Chief Strategy Officer.
Why this rating

Transformational M&A + $120M capital raise = 16x pre-deal equity cap for $7.3M company. Dramatically extends runway, validates lead asset, positions for clinic catalysts.

Tradability signal
NO TRADE

No trade: positive news with only +0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.52% over 4 hrs, n=28). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$5.96 ▼ 0.67%
at our read · unknown
$6.00
+10 min · unknown
$6.00 ▲ 0.00%
+30 min · unknown
$6.06 ▲ 1.00%
+1 hr · unknown
$6.19 ▲ 3.17%
+4 hrs · unknown
$6.09 ▲ 1.58%

The stock had already moved +0.67% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ BOLT · stock on Yahoo Finance ↗

See more from November 12, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.